Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SNY vs UNOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNY Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

SNY Overall Winner 6-Pillar Tally: SNY 5 – 0 UNOV (1 Tie) Matrix Metrics: SNY 7 – 3 UNOV

As of Nov 16, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SNY carries a Unified Composite Score of 31.7/100 (SELL) at $48.39 (8.9x Forward P/E, 22.3% operating margin), whereas UNOV carries 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. SNY 31.7/100 SELL), SNY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (22.3% vs. N/A operating margin) and revenue trajectory (+15.7% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNY vs UNOV
SNY NASDAQ Head-to-Head Winner
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Pharmaceutical Preparations
$48.39
+0.04% 1D
Market Cap $116.1B
TTM Revenue $30.1B
Forward P/E 8.9x
Beta / 30D Vol 0.21β · 27% Vol
Unified Composite Score
31.7 / 100 SELL
Tech 50.0 Fund 28.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 76
RSI-14: 76.4 · SMA20: $45.08 · SMA50: $42.76
UNOV Cboe BZX
Innovator U.S. Equity Ultra Buffer ETF - November
Pharmaceutical Preparations
$41.13
-0.95% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.46β · 11% Vol
Unified Composite Score
58.7 / 100 HOLD
Tech 48.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.3 · SMA20: $41.59 · SMA50: $41.48

6-Pillar Scorecard Institutional Category Breakdown (SNY 5 – 0 UNOV)

Columns: Metric · SNY · UNOV
1. Valuation Multiples SNY
Forward P/E 8.9x N/M
Trailing P/E 24.1x N/M
PEG Ratio 1.78x N/M
EV / Revenue 3.9x N/M
2. Growth & Scale SNY
Revenue Growth (YoY) +15.7% N/A
Earnings Growth (YoY) +9.4% N/A
TTM Revenue (USD) $30.1B N/A
Market Cap $116.1B N/A
3. Profitability & Quality SNY
Gross Margin 74.3% N/A
Operating Margin 22.3% N/A
Net Profit Margin 8.2% N/A
Return on Equity (ROE) 5.7% N/A
4. Balance Sheet & Cash Flow SNY
Cash Generation (TTM) $8.72B EBITDA N/A
Cash Flow Margin 29.0% EBITDA Mgn N/A
Net Cash / Leverage $34.11 Book/Sh · 5.7% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 22.0% (43rd %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNY
OpEx & R&D Intensity 52.0% of Rev ($15.6B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNY (7) vs UNOV (3)
Institutional Metric SNY UNOV Criterion Row Edge
Market Capitalization
Scale
$116.1B N/A Larger Scale SNY
Trailing P/E Ratio
Valuation
24.1x N/M Lower Multiple SNY
Forward P/E Ratio
Valuation
8.9x N/M Lower Multiple SNY
Revenue Growth (YoY)
Growth
+15.7% N/A Higher Growth SNY
Operating Margin (TTM)
Profitability
22.3% N/A Higher Margin SNY
Net Profit Margin
Profitability
8.2% N/A Higher Margin SNY
Return on Equity (ROE)
Capital Efficiency
5.7% N/A Higher ROE SNY
52-Week Range Position
Momentum
68% ($39–$53) 84% ($37–$42) Stronger Trend UNOV
Beta / 30D Volatility
Risk Regime
0.21β · 27% Vol 0.46β · 11% Vol Lower Realized Risk UNOV
Unified Institutional Score
Composite Signal
31.7 / 100 (SELL) 58.7 / 100 (HOLD) Higher Composite UNOV
Trailing 12M Revenue (USD)
Operating Scale
$30.1B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.78x PEG · 3.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.72B EBITDA ($34.11 Book/Sh · 5.7% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNY +20.13 pp
SNY: +19.16% · UNOV: -0.97%
3M Horizon SNY +7.17 pp
SNY: +7.61% · UNOV: +0.44%
6M Horizon SNY +7.72 pp
SNY: +11.14% · UNOV: +3.42%
1Y Horizon UNOV +17.08 pp
SNY: -7.55% · UNOV: +9.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SNY vs UNOV. Trailing 12-month operating profitability (SNY 22.3% vs UNOV N/A) and valuation multiples (SNY 8.9x vs UNOV N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SNY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$30.1B
Gross Margin74.3%
Op. Margin22.3%
ROE / Fwd P/E5.7% · 8.9x
UNOV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.0%
IV Percentile 43rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNY Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $116.1B market capitalization and 22.3% operating margin.
OpEx & R&D Reinvestment 52.0% of Rev ($15.6B)
90D Engineering Disclosures 0 Published
UNOV Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SNY vs UNOV Key Questions & Quantitative Answers

As of Nov 16, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SNY carries a Unified Composite Score of 31.7/100 (SELL) at $48.39 (8.9x Forward P/E, 22.3% operating margin), whereas UNOV carries 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. SNY 31.7/100 SELL), SNY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (22.3% vs. N/A operating margin) and revenue trajectory (+15.7% vs. N/A YoY).

SNY leads the Growth & Scale pillar: SNY posts +15.7% YoY revenue growth and +9.4% YoY earnings growth on $30.1B TTM revenue (74.3% gross margin, 22.3% operating margin), compared with UNOV at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, SNY generates $30.1B in USD-normalized revenue versus N/A for UNOV. In operating R&D and SG&A reinvestment, SNY deploys 52.0% of Rev ($15.6B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UNOV.

SNY screens cheaper on headline valuation multiples. SNY trades at 8.9x Forward P/E, 24.1x Trailing P/E, 1.78x PEG, and 3.9x EV/Revenue (29.0% EBITDA margin), whereas UNOV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNY (5.7% ROE) versus UNOV (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, SNY carries 22.0% implied volatility (43rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.21β · 27% Vol realized risk). By comparison, UNOV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 11% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) Research Suite

Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.